PSYONIC
Designs and manufactures advanced bionic upper-limb prosthetics, including the Ability Hand with touch feedback.
Website: https://www.psyonic.io/
Cover Block
PUBLIC
| Attribute | Value |
|---|---|
| Name | PSYONIC |
| Tagline | Designs and manufactures advanced bionic upper-limb prosthetics, including the Ability Hand with touch feedback. |
| Headquarters | San Diego, United States |
| Founded | 2015 |
| Stage | Series A |
| Business Model | Hardware + Software |
| Industry | Deeptech |
| Technology | Robotics |
| Geography | North America |
| Growth Profile | Venture Scale |
| Founding Team | Academic Spinout |
| Funding Label | Undisclosed |
Links
PUBLIC
- Website: https://www.psyonic.io/
- LinkedIn: https://www.linkedin.com/company/psyonicinc
- StartEngine Offering: https://www.startengine.com/offering/psyonic
Executive Summary
PUBLIC PSYONIC is a venture-scale developer of advanced bionic prosthetics, attracting attention for its dual focus on high-performance hardware and a novel capital strategy aimed at accessibility. The company's flagship Ability Hand is a multi-articulated myoelectric prosthesis that provides touch feedback and claims to be the fastest bionic hand on the market, closing in 0.2 seconds [PSYONIC, retrieved 2026]. Founded in 2015 by Dr. Aadeel Akhtar, the company emerged from his graduate research at the University of Illinois at Urbana-Champaign, where he combined a PhD in Neuroscience and an MD to address a problem he first encountered as a child [Perplexity Sonar Pro Brief, retrieved 2026]. The product's wedge is a combination of technical performance and a stated goal of affordability, targeting a market where traditional multi-articulated hands can cost between $30,000 and $100,000 [Perplexity Sonar Pro Brief, retrieved 2026].
PSYONIC's funding path has been unconventional, relying heavily on Regulation Crowdfunding campaigns via platforms like StartEngine rather than traditional venture-led rounds. The company has reported raising over $1 million through one such campaign and secured a $1 million offer on Shark Tank in 2024, which implied a $50 million valuation [PSYONIC, 2023] [CNBC, Feb 2024]. Its business model is a hardware-plus-software sale through prosthetic clinics, designed to fit within existing U.S. insurance reimbursement frameworks. Over the next 12-18 months, the critical watchpoints are the scalability of its crowdfunding-dependent capital structure, the translation of its philanthropic Ability Fund partnership into broader commercial adoption, and the progress of its exploratory work applying bionic technology to robotics.
Data Accuracy: YELLOW -- Core product claims and founder background are well-documented, but key financial details and funding round structures are reported from varied sources without independent verification.
Taxonomy Snapshot
| Axis | Classification |
|---|---|
| Stage | Series A |
| Business Model | Hardware + Software |
| Industry / Vertical | Deeptech |
| Technology Type | Robotics |
| Geography | North America |
| Growth Profile | Venture Scale |
| Founding Team | Academic Spinout |
| Funding | Undisclosed |
Company Overview
PUBLIC
PSYONIC’s origin is a direct translation of academic research into a commercial venture, rooted in the University of Illinois at Urbana-Champaign. Founder and CEO Aadeel Akhtar began developing the core technology for the Ability Hand as part of his graduate work, which spanned a PhD in Neuroscience, an MS in Electrical & Computer Engineering, and an MD [Perplexity Sonar Pro Brief, retrieved 2026]. The company was formally founded in 2015 and is headquartered in San Diego, California, having graduated from the University of Illinois Research Park incubator [researchpark.illinois.edu, retrieved 2026] [PSYONIC, retrieved 2026].
The company’s early milestones reflect a capital strategy built on non-dilutive grants and public crowdfunding rather than traditional venture rounds. PSYONIC received a $1.4 million grant in 2020, according to a local publication [sandiegomagazine.com, retrieved 2026]. A significant inflection point was a 2023 equity crowdfunding campaign on StartEngine, which the company reported had raised over $1 million [PSYONIC, 2023]. This was followed by a $4.1 million raise in early 2024, also attributed to a seed funding round [slashgear.com, retrieved 2026] [news.luc.edu, retrieved 2026]. The company gained broader public visibility in February 2024 when it secured a $1 million offer on the television program Shark Tank for 6% of the company, implying a valuation of approximately $50 million [CNBC, Feb 2024].
A key operational milestone was the May 2024 launch of the Ability Fund, a philanthropic partnership with the Limbs for Life Foundation designed to provide devices to individuals who cannot afford them [PSYONIC, May 2024]. The company also lists a pilot application of its bionic hand technology for robotics, including work with Mercedes Benz and Apptronik [PSYONIC, retrieved 2026].
Data Accuracy: YELLOW -- Core founding and location details are confirmed by the company and university sources. Specific funding amounts and dates are reported by multiple outlets, but lead investors and precise round structures are not publicly detailed.
Product and Technology
MIXED PSYONIC's flagship product is the Ability Hand, a multi-articulated myoelectric prosthetic hand that differentiates itself on three core technical claims: speed, sensory feedback, and durability. The company states the hand closes in 0.2 seconds, positioning it as the fastest bionic hand available [PSYONIC, retrieved 2026]. Integrated sensors detect pressure on the fingertips and communicate that sensation to the user via vibrations, a feature the company markets as touch feedback [PSYONIC, retrieved 2026]. The device is also designed for daily use, with specifications listing impact and water resistance and a weight of 490 grams [PSYONIC, retrieved 2026].
Beyond the core prosthetic, PSYONIC has publicly disclosed a secondary application for its technology: robotics. The company offers products for robots, citing a manufacturing pilot with Mercedes Benz and Apptronik humanoid robots [PSYONIC, retrieved 2026]. The commercial model for the Ability Hand is built around integration into the existing U.S. healthcare reimbursement system; the hand is designed to be prescribed and reimbursed via established prosthetic coding, a critical wedge for accessibility [Perplexity Sonar Pro Brief, retrieved 2026]. The underlying technology stack (inferred from job postings and founder background) likely combines custom electromechanical actuators, embedded systems for EMG signal processing, and proprietary algorithms for sensor fusion and control.
Data Accuracy: GREEN -- Product specifications are confirmed by the company's own materials and repeated in independent press coverage. The robotics application and reimbursement strategy are noted in public sources, though specific payer contracts are not detailed.
Market Research
PUBLIC
The market for advanced bionic limbs sits at a critical inflection point, driven by technological maturation, demographic pressures, and a growing focus on accessibility that is reshaping the economics of medical hardware.
Demand is underpinned by a consistent, non-cyclical need. An estimated 185,000 people undergo an amputation in the United States each year, with vascular disease and diabetes accounting for the majority of cases [CDC]. Upper-limb amputations, while less common, represent a segment where functional restoration through advanced prosthetics can have a profound impact on quality of life. The primary demand drivers are aging populations with higher rates of diabetes, continued improvements in trauma care leading to higher survival rates, and a growing cultural expectation for assistive technology that enables full participation in work and daily life.
Tailwinds specific to the bionics sector are accelerating. Advances in materials science, sensor miniaturization, and machine learning algorithms for intuitive control are making sophisticated devices more reliable and manufacturable. Concurrently, the broader robotics and humanoid AI sector is creating a secondary market for advanced manipulators, potentially driving down component costs through shared supply chains and R&D. PSYONIC's pilot with Mercedes Benz and Apptronik, noted on its website, is a direct example of this cross-pollination [PSYONIC, retrieved 2026].
Market sizing for multi-articulated bionic hands is fragmented, with most figures coming from industry analysts rather than standardized public reports. A frequently cited range for traditional devices is $30,000 to $100,000 per unit [Perplexity Sonar Pro Brief, retrieved 2026]. Using this as an anchor, the serviceable addressable market (SAM) for upper-limb devices can be modeled. If an estimated 10% of the roughly 2 million people living with limb loss in the U.S. are upper-limb amputees, and a fraction of those are candidates for a myoelectric device, the U.S. SAM likely sits in the low hundreds of millions of dollars annually. The global figure is larger but complicated by vastly different reimbursement landscapes.
| Metric | Value |
|---|---|
| Traditional Bionic Hand | 30000 USD (low-end) |
| Traditional Bionic Hand | 100000 USD (high-end) |
The chart illustrates the established price anchor PSYONIC's product is positioned against; the company's stated wedge of affordability aims to capture share by operating below this band, though its specific price point is not publicly disclosed.
Key adjacent markets include both substitutes and complements. Traditional body-powered cable prosthetics remain a low-cost substitute, while emerging technologies like targeted muscle reinnervation (TMR) surgery and advanced osseointegration are complementary procedures that can enhance the functionality of a device like the Ability Hand. The regulatory environment is a defining force. In the U.S., reimbursement through Medicare, Medicaid, and private insurers via established HCPCS (Healthcare Common Procedure Coding System) codes is the primary commercial gateway. A product's success hinges on securing these codes and negotiating favorable coverage policies, a process that is not detailed in PSYONIC's public materials.
Data Accuracy: YELLOW -- Market size figures are analogies or ranges from industry briefs; demographic drivers are from public health data. Specific SAM/SOM for PSYONIC is not publicly modeled.
Competitive Landscape
MIXED PSYONIC operates in a specialized hardware segment where performance, price, and access to clinical channels define the competitive map, not just technical specifications.
The company's flagship Ability Hand is positioned against a mix of established medical device incumbents, newer venture-backed entrants, and philanthropic initiatives. A comparison of key players based on public information shows the following landscape.
| Company | Positioning | Stage / Funding | Notable Differentiator | Source |
|---|---|---|---|---|
| PSYONIC | Affordable, high-speed bionic hand with touch feedback | Series A; raised via equity crowdfunding and grants | Speed (0.2s close), integrated touch feedback, focus on accessibility via insurance & philanthropy | [PSYONIC, retrieved 2026], [CNBC, Feb 2024] |
| Össur | Global leader in non-invasive orthopedics and prosthetics | Public company (ICELAND: OSSR) | Deep clinical relationships, broad product portfolio, global manufacturing and distribution | [Össur] |
| Open Bionics | Developer of affordable, user-friendly bionic arms, often with stylized designs | Venture-backed (e.g., Downing Ventures) | Focus on design aesthetics and user experience, particularly for younger users; lower price point | [Open Bionics] |
| COVVI | Maker of the COVVI Hand, a multi-grip bionic hand | Venture-backed (e.g., Parkwalk Advisors) | Emphasizes robustness and everyday reliability; developed by former Touch Bionics team | [COVVI] |
| Esper Bionics | Developer of AI-powered bionic hands with adaptive grip | Early-stage venture-backed | Integrates machine learning for pattern recognition and predictive grip control | [Esper Bionics] |
The competitive map splits into three tiers. The first is the high-end incumbent segment, dominated by large, publicly traded orthopedics companies like Össur and its subsidiary Touch Bionics. These players hold significant advantages in clinical validation, reimbursement infrastructure, and global distributor networks. Their products are often considered the clinical standard but carry premium price tags, reportedly between $30,000 and $100,000 [Perplexity Sonar Pro Brief, retrieved 2026]. The second tier consists of venture-scale challengers, including PSYONIC, Open Bionics, COVVI, and Esper Bionics. These companies compete on specific wedges: Open Bionics on design and cost, COVVI on durability, Esper on AI, and PSYONIC on speed and sensory feedback. The third tier includes adjacent substitutes, such as body-powered hooks, cosmetic prostheses, and research prototypes from academic labs, which compete primarily on cost or specific functional niches.
PSYONIC's defensible edge today rests on two technical claims and one commercial approach. The technical claims are the hand's closing speed of 0.2 seconds and its integrated touch feedback system, both of which are repeatedly cited in company materials and third-party reviews [PSYONIC, retrieved 2026], [thegadgetflow.com, retrieved 2026]. These features address functional gaps in daily use, like quickly grabbing a falling object or sensing grip pressure. The commercial edge is the company's explicit focus on affordability and accessibility through the existing U.S. insurance reimbursement system and its philanthropic Ability Fund partnership with Limbs for Life [PSYONIC, May 2024]. This dual-track model aims to build brand goodwill and demonstrate clinical utility. The durability of the technical edge is perishable, however, as competitors can engineer similar speed or feedback. The commercial edge tied to reimbursement is more defensible if PSYONIC secures broad payer contracts, but those details are not public.
The company's most significant exposure is in distribution and scale. Incumbents like Össur have decades-deep relationships with prosthetic clinics and orthotists, the critical gatekeepers for prescription. PSYONIC must convince these clinicians to adopt a new device, which involves training, support, and proven long-term reliability,factors where a startup has less track record. Furthermore, while PSYONIC's capital strategy of equity crowdfunding provides non-dilutive growth capital, it may limit access to the large, strategic venture rounds that competitors like Open Bionics or Esper Bionics could use to accelerate sales force expansion or international market entry.
The most plausible 18-month scenario involves further market segmentation. If insurance reimbursement for advanced bionic hands expands and simplifies, PSYONIC's focus on coding and affordability could make it a winner in cost-conscious clinical settings in the U.S. Conversely, if a competitor like Esper Bionics successfully commercializes its AI adaptive grip and secures a major partnership with a national clinic chain, it could capture the "smart prosthetic" narrative and leave PSYONIC competing primarily on speed, a single metric. The loser in any scenario is likely a company that fails to move beyond early adopters and into the mainstream clinical workflow, regardless of its technical specifications.
Data Accuracy: YELLOW -- Competitor profiles and PSYONIC's positioning are based on company materials and common industry references. Specific funding stages for competitors and precise pricing are not uniformly disclosed across all players.
Opportunity
PUBLIC The potential outcome for PSYONIC is the creation of a high-volume, accessible bionic limb platform that redefines the economics and performance expectations of the global prosthetic market.
The headline opportunity is to become the category-defining, high-volume supplier of advanced upper-limb prosthetics, displacing legacy, high-cost devices by proving that superior performance can be delivered at a lower price point. This outcome is reachable because the company has already demonstrated a working product with distinct technical advantages, such as speed and integrated touch feedback, and has structured its business to align with existing insurance reimbursement pathways [PSYONIC, retrieved 2026]. The wedge is not just technology but a combined value proposition of affordability and accessibility, a gap that persists in a market where traditional devices can cost between $30,000 and $100,000 [Perplexity Sonar Pro Brief, retrieved 2026]. Success here would mean PSYONIC transitions from a niche medical device maker to a volume-driven hardware platform.
Growth scenarios outline concrete paths to achieve that scale. The company's current activities and partnerships provide plausible catalysts for each path.
| Scenario | What happens | Catalyst | Why it's plausible |
|---|---|---|---|
| Dominance in U.S. Clinical Channels | PSYONIC becomes the default prosthetic hand prescribed by U.S. prosthetists for myoelectric fittings, capturing significant market share. | Widespread insurance coverage and favorable reimbursement codes are secured, making the Ability Hand a low-friction choice for clinicians. | The product is explicitly designed for the existing U.S. prosthetic coding system [Perplexity Sonar Pro Brief, retrieved 2026], and the company's partnership with the Limbs for Life Foundation builds clinical and payer relationships [PSYONIC, May 2024]. |
| Platform Expansion into Robotics | The core actuation and sensor technology becomes a preferred component for humanoid and industrial robotic hands, creating a second, high-margin revenue stream. | A successful manufacturing pilot with a major partner like Mercedes-Benz and Apptronik leads to a commercial supply agreement [PSYONIC, retrieved 2026]. | The company already markets its technology for robotic applications, indicating a strategic intent to diversify beyond the medical vertical. |
| International Scale via Philanthropic Model | The "Ability Fund" model is replicated with NGOs globally, driving volume, brand goodwill, and establishing a beachhead in price-sensitive markets. | A major philanthropic or corporate sponsor commits to funding thousands of devices through the established Limbs for Life partnership. | The fund has been launched and provides a turnkey mechanism for large-scale charitable distribution [PSYONIC, May 2024], demonstrating a working model for impact-driven scale. |
What compounding looks like is a volume-driven improvement in unit economics that reinforces the affordability wedge. Each device sold through clinical channels generates data on reliability and user outcomes, which can be used to streamline manufacturing, reduce costs, and strengthen reimbursement claims. This creates a feedback loop: lower costs enable more competitive pricing or higher margins, which fuels further investment in R&D or sales expansion. Early signs of this flywheel are present in the company's use of crowdfunding to finance growth, which, while unconventional, demonstrates an ability to aggregate capital from a broad base to support manufacturing scale [PSYONIC, 2023]. Success in robotics could further amortize R&D and manufacturing overhead across two markets, accelerating the cost-down trajectory for the medical product.
The size of the win can be framed by looking at the valuation of established medical device peers and the total addressable market. Public competitors in the orthopedic and prosthetic space, such as Össur, trade at market capitalizations in the multi-billion dollar range. If PSYONIC successfully executes on the "Dominance in U.S. Clinical Channels" scenario and captures a meaningful portion of the upper-limb prosthetic market, a valuation trajectory toward the high hundreds of millions or low billions is plausible. This is a scenario-based outcome, not a forecast, but it illustrates the magnitude of the opportunity if the company can transition from a startup to a volume platform. The underlying TAM for advanced prosthetic devices is sustained by demographic trends and medical advances, providing a stable foundation for growth.
Data Accuracy: YELLOW -- The core product claims and partnership details are confirmed by the company. Market pricing and reimbursement strategy are cited from a secondary analysis, and growth scenarios are extrapolated from announced initiatives.
Sources
PUBLIC
[PSYONIC, retrieved 2026] PSYONIC | https://www.psyonic.io/
[PSYONIC, 2023] PSYONIC's equity raise reaches $1 Million | https://www.psyonic.io/news/psyonic-and-limbs-for-life-launch-the-ability-fund
[CNBC, Feb 2024] 'Shark Tank': How prosthetics startup Psyonic landed $1 million offer | https://www.cnbc.com/2024/02/28/shark-tank-how-prosthetics-startup-psyonic-landed-1-million-offer.html
[Perplexity Sonar Pro Brief, retrieved 2026] Perplexity Sonar Pro Brief | https://www.perplexity.ai
[researchpark.illinois.edu, retrieved 2026] PSYONIC - Research Park - University of Illinois | https://researchpark.illinois.edu/impact/startup-graduates/psyonic/
[sandiegomagazine.com, retrieved 2026] PSYONIC grant coverage | https://www.sandiegomagazine.com/
[slashgear.com, retrieved 2026] PSYONIC seed funding | https://www.slashgear.com/
[news.luc.edu, retrieved 2026] PSYONIC funding coverage | https://news.luc.edu/
[PSYONIC, May 2024] PSYONIC and Limbs for Life Launch the Ability Fund | https://www.psyonic.io/news/psyonic-and-limbs-for-life-launch-the-ability-fund
[thegadgetflow.com, retrieved 2026] The Ability Hand review | https://www.thegadgetflow.com/
Articles about PSYONIC
- PSYONIC's Bionic Hand Closes a Grip in 0.2 Seconds — The San Diego startup, funded through equity crowdfunding and a Shark Tank deal, is aiming to make advanced prosthetics accessible through existing insurance codes.